Oncoprotein SND1 hijacks nascent MHC-I heavy chain to ER-associated degradation, leading to impaired CD8 + T cell response in tumor.

Yuan Wang,Xinting Wang,Xiaoteng Cui,Yue Zhuo,Hongshuai Li,Chuanbo Ha,Lingbiao Xin,Yuanyuan Ren,Wei Zhang,Xiaoming Sun,Lin Ge,Xin Liu,Jinyan He,Tao Zhang,Kai Zhang,Zhi Yao,Xi Yang,Jie Yang

DOI: https://doi.org/10.1126/sciadv.aba5412

IF: 13.6

2020-01-01

Science Advances

Abstract:SND1 is highly expressed in various cancers. Here, we identify oncoprotein SND1 as a previously unidentified endoplasmic reticulum (ER) membrane-associated protein. The amino-terminal peptide of SND1 predominantly associates with SEC61A, which anchors on ER membrane. The SN domain of SND1 catches and guides the nascent synthesized heavy chain (HC) of MHC-I to ER-associated degradation (ERAD), hindering the normal assembly of MHC-I in the ER lumen. In mice model bearing tumors, especially in transgenic OT-I mice, deletion of SND1 promotes the presentation of MHC-I in both B16F10 and MC38 cells, and the infiltration of CD8(+) T cells is notably increased in tumor tissue. It was further confirmed that SND1 impaired tumor antigen presentation to cytotoxic CD8(+) T cells both in vivo and in vitro. These findings reveal SND1 as a novel ER-associated protein facilitating immune evasion of tumor cells through redirecting HC to ERAD pathway that consequently interrupts antigen presentation.